

The 14th International Forum of The Japanese Society of Gastroenterology

DAY2

Time & Date : 9 : 00~17 : 00, Friday, April 25, 2025

Place : Room 5 (Ohgi)

Main Theme : “Advances in gastrointestinal and hepato-pancreato-biliary immune-mediated inflammatory diseases”

1. Advance in autoimmune liver disease (9 : 00~10 : 10)

Moderators : Atsushi Tanaka (Department of Medicine, Teikyo University School of Medicine, Japan)

Atsumasa Komori (Clinical Research Center, NHO Nagasaki Medical Center, Japan)

- IF1-1 Therapeutic developments in autoimmune liver diseases
(Department of Transplantation Medicine, Division of Surgery and Specialized Medicine, Oslo University Hospital, Norway)
Tom Hemming Karlsen
- IF1-2 Recompensation Criteria in Patients with Autoimmune Hepatitis-Related decompensated Cirrhosis
(Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University, China)
Xiong Ma
- IF1-3 The gut-liver axis in primary sclerosing cholangitis
(Division of Gastroenterology and Hepatology, Keio University School of Medicine, Tokyo, Japan)
Nobuhiro Nakamoto, Masataka Ichikawa, Haruka Okada, Nobuhito Taniki, Takanori Kanai
- IF1-4 Identification of novel autoantibody using human protein microarray in patients with autoimmune hepatitis
(Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan)
Kazumichi Abe, Jun Wada, Naoto Abe, Tatsuro Sugaya, Yosuke Takahata, Masashi Fujita, Manabu Hayashi, Hiromasa Ohira

2. Advances in immune-related pancreaticobiliary disease (10 : 20~11 : 30)

Moderators : Yuzo Kodama (Department of Gastroenterology, Kobe University Graduate School of Medicine, Japan)

Hiroyuki Isayama (Department of Gastroenterology, Juntendo University, Japan)

- IF2-1 Exploring clinical subtypes and treatment strategies of IgG4-related disease
(Department of Rheumatology, Peking Union Medical College Hospital, China)
Wen Zhang, Linyi Peng, Jiaxin Zhou, Yunyun Fei, Yuxue Nie

- IF2-2 Proximal versus Distal IgG4-Sclerosing Cholangitis : Distinct Disease Entities?
(Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Korea)
Tae Jun Song
- IF2-3 Advances in immune-related pancreaticobiliary disease
(Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Japan)
Masahiro Shiokawa, Masataka Yokode, Takeshi Kuwada, Yoshihiro Nishikawa, Yuya Muramoto, Hiroshi Seno
- IF2-4 The 2024 diagnostic criteria for primary sclerosing cholangitis
(Department of Gastroenterology, Nagoya City University Midori Municipal Hospital, Japan)
Itaru Naitoh
(Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Japan)
Hiroyuki Isayama
(Department of Medicine, Teikyo University School of Medicine, Japan)
Atsushi Tanaka

3. Advances in inflammatory bowel disease (14 : 30~15 : 40)

Moderators : Tadakazu Hisamatsu (Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Japan)

Akira Andoh (Department of Gastroenterology, Shiga University of Medical Science, Japan)

- IF3-1 Optimization the non-invasive tools to predict endoscopic severity for IBD patients
(Department of Internal Medicine, National Taiwan University Hospital, Taiwan)
Shu-Chen Wei
- IF3-2 Redox-induced Stabilization of AMBRA1 by USP7 Promotes Intestinal Oxidative Stress and Colitis through Antagonizing DUB3-mediated NRF2 Deubiquitination
(Department of Gastroenterology, Rui Jin Hospital, affiliate to Shanghai Jiao Tong University, school of Medicine, China.)
Yubei Gu
(Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, China)
Xu Weimin, Hua Zhebin, Wang Yaosheng, Liu ChenYing, Du Peng
- IF3-3 Subcutaneous infliximab for the treatment of inflammatory bowel disease
(Department of Gastroenterology and Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea)
Byong Duk Ye

- IF3-4 The involvement of MEFV gene mutation in the pathophysiology of inflammatory bowel disease unclassified.
(Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Japan)
Hiroschi Nakase, Wagatsuma Kohei

4. Advances in immune-related adverse event (15 : 50~17 : 00)

Moderators : Yasuo Hamamoto (Department of Medical Oncology, Institute of Science Tokyo, Japan)

Hayato Nakagawa (Department of Gastroenterology and Hepatology, Mie University, Japan)

- IF4-1 Cancer immunotherapy and immune-related adverse events~lessons learned
(Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan/Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan/Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan)
Chih-Hung Hsu
- IF4-2 Friend or Foe? Advances in the management of irAE
(Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong)
Ka On Lam
- IF4-3 Appropriate management of patients with immune-related gastrointestinal/hepatobiliary adverse events associated with immune checkpoint inhibitors.
(Division of General Internal Medicine, Mitsui Memorial Hospital, Japan)
Nobuyoshi Minemura
- IF4-4 irAE minimal requirements to know as an oncologist
(Nara Prefecture General Medical Center, Japan)
Teruhisa Azuma